Treatment of adult ALL patients with third-generation CD19-directed CAR T cells: results of a pivotal trial
Third-generation chimeric antigen receptor (CAR)-engineered T cells (CARTs) might improve clinical outcome of patients with B cell malignancies. This is the first report on a third-generation CART dose-escalating, phase-1/2 investigator-initiated trial treating adult patients with refractory and/or...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
22 July 2023
|
| In: |
Journal of hematology & oncology
Year: 2023, Volume: 16, Pages: 1-17 |
| ISSN: | 1756-8722 |
| DOI: | 10.1186/s13045-023-01470-0 |
| Online Access: | Resolving-System, kostenfrei: https://dx.doi.org/10.1186/s13045-023-01470-0 |
| Author Notes: | Maria-Luisa Schubert, Anita Schmitt, Angela Hückelhoven-Krauss, Brigitte Neuber, Alexander Kunz, Philip Waldhoff, Dominik Vonficht, Schayan Yousefian, Lea Jopp-Saile, Lei Wang, Felix Korell, Anna Keib, Birgit Michels, Dominik Haas, Tim Sauer, Patrick Derigs, Andreas Kulozik, Joachim Kunz, Petra Pavel, Sascha Laier, Patrick Wuchter, Johann Schmier, Gesine Bug, Fabian Lang, Nicola Gökbuget, Jochen Casper, Martin Görner, Jürgen Finke, Andreas Neubauer, Mark Ringhoffer, Denise Wolleschak, Monika Brüggemann, Simon Haas, Anthony D. Ho, Carsten Müller-Tidow, Peter Dreger and Michael Schmitt |
| Summary: | Third-generation chimeric antigen receptor (CAR)-engineered T cells (CARTs) might improve clinical outcome of patients with B cell malignancies. This is the first report on a third-generation CART dose-escalating, phase-1/2 investigator-initiated trial treating adult patients with refractory and/or relapsed (r/r) acute lymphoblastic leukemia (ALL). |
|---|---|
| Item Description: | Gesehen am 02.02.2024 |
| Physical Description: | Online Resource |
| ISSN: | 1756-8722 |
| DOI: | 10.1186/s13045-023-01470-0 |